Advertisement

Mechanism of Humoral Xenograft Rejection

  • L. C. Paul

Abstract

During the 1960s, as allogeneic clinical organ transplantation became to some extent successful while the supply of organs was limited, a few clinical xenotransplants were performed with organs from subhuman primates [1-3]. The increased availability of human organs after the introduction of brain death criteria, together with failure to achieve any long-term success with xenogeneic organs, however, dampened enthusiasm for xenotransplantation considerably. The current success rate of allotransplantation together with the wider acceptance of high-risk patients has, however, caused a tremendous increase in demands for organs and stimulated a renewed interest in the possibility of xenotransplantation.

Keywords

Membrane Attack Complex Hyperacute Rejection Xenograft Rejection Cobra Venom Factor Classical Route 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Reemtsma K, McCracken BH, Schlegel JU, Pearl MA, Pearce CW, De Witl CW, Smith PE, Hewitt RL, Flinner RL, Creech Jr. O. Renal heterotransplantation in man. Ann. Surgery 160:384–410, 1964.Google Scholar
  2. 2.
    Starzl TE, Marchioro TL, Peters GN, Kirkpatrick CH, Wilson WEC, Porter KA, Rifkind D, Ogden DA, Hitchcock CR, Waddell WR. Renal heterotransplantation from baboon to man: experience with six cases. Transplantation 2:752–776, 1964.PubMedGoogle Scholar
  3. 3.
    Hardy JD, Chavez CM. The first heart transplant in man. Developmental animal investigations with analysis of the 1964 case in the light of current clinical experience. Am. J. Cardiol. 22:772–781, 1968.PubMedGoogle Scholar
  4. 4.
    Steinmuller D. Cross-species transplantation in embryonic and neonatal animals. Transplant. Proc. 2:438–445, 1970.PubMedGoogle Scholar
  5. 5.
    Calne RY. Organ transplantation between widely disparate species. Transplant. Proc. 2:550–553, 1970.PubMedGoogle Scholar
  6. 6.
    Kissmeyer-Nielsen F, Olsen, S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts associated with pre-existing humoral antibodies against donor cells. Lancei 1:662–665, 1966.Google Scholar
  7. 7.
    Paul LC, Baldwin WM III, van Es LA. Vascular endothelial alloantigens in renal transplantation. Transplantation 40:117–123, 1985.PubMedGoogle Scholar
  8. 8.
    Baldwin WM III, Paul LC, Claas FHJ, Daha MR. Antibody-mediated events in transplantation: challenges to past dogma and hopes for the future. In: Progress in Transplantation, Vol. 3. Morris PJ, Tilney NL (eds), Churchill Livingstone; Edinburgh, London, Melbourne, New York, 1986, pp. 85–114.Google Scholar
  9. 9.
    Trento A, Hardesty RL, Griffith P, Zerbe T, Kormos RL, Bahnson HT. Role of antibody to vascular endothehal cells in hyperacute rejection in patients undergoing cardiac transplantation. J. Thorac. Cardiovasc. Surg. 95:37–41, 1988.PubMedGoogle Scholar
  10. 10.
    Eichwald EJ, Shelby J. Is delayed-type hyper-sensitivity the pathway of hyperacute rejection in transplanted mouse hearts ? Transplant. Proc. 19:426–427, 1987.PubMedGoogle Scholar
  11. 11.
    Hammer C, Chaussy CH, Brendel W. Preformed natural antibodies in animals and man. Outlook on xenotransplantation. Europ. Surg. Res. 5:162–166, 1973.Google Scholar
  12. 12.
    Tilney NL, Kupiec-Weglinski JW, Heideche CD, Lear PA, Strom TB. Mechanisms of rejection and prolongation of vascularized organ allografts. Immunol. Rev. 77: 185–216, 1987.Google Scholar
  13. 13.
    Couser WG, Darby C, Salant DJ, Adler S, Stilmant MM, Lowenstein LM. Anti-GBM antibody-induced proteinuria in isolated perfused rat kidney. Am. J. Physiol. 249: F241–F250, 1985.PubMedGoogle Scholar
  14. 14.
    Boyce NW, Holdsworth SR. Direct anti-GMB antibody-induced alterations in glomerular permselectivity. Kidney Int. 30:666–672, 1986.PubMedGoogle Scholar
  15. 15.
    Mendrick DL, Rennke HG. I. Induction of proteinuria in the rat by a monoclonal antibody against SGF-115/107. Kidney Int. 33:818–830, 1988.PubMedGoogle Scholar
  16. 16.
    Porter KA. The effects of antibodies on human renal allografts. Transplant. Proc. 8: 189–197, 1976.PubMedGoogle Scholar
  17. 17.
    Baker PJ, Osofsky SG. Activation of human complement by heat-killed, human kidney cells grown in cell culture. J. Immunol. 124:81–86, 1980.PubMedGoogle Scholar
  18. 18.
    Reid KBM. Proteins involved in the activation and control of the two pathways of human complement. Biochem. Soc. Trans. 11:1–12, 1983.PubMedGoogle Scholar
  19. 19.
    Minta JO, Movat HZ. The complement system and inflammation. Curr. Top. Path. 68: 135–178, 1979.Google Scholar
  20. 20.
    Fearon DT, Austen KF. Initiation of C3 cleavage in the alternative complement pathway. J. Immunol. 115:1357–1361, 1975.PubMedGoogle Scholar
  21. 21.
    Fishelson Z, Pangburn MK, Muller-Eberhard HJ. Characterization of the initial C3 convertase of the alternative pathway of human complement. J. Immunol 132: 1430–1434, 1989.Google Scholar
  22. 22.
    Whaley K, Ruddy S. Modulation of the alternative complement pathway by BIH. J. Exp. Med. 144:1147–1163, 1976.PubMedGoogle Scholar
  23. 23.
    Kazatchkine MD, Fearon DT, Austen KF. Human alternative pathway membrane associated siahc acid regulates the competition between B and BIH for cell bound C3b. J. Immunol 122:75–81, 1979.PubMedGoogle Scholar
  24. 24.
    Fearon DT, Austen KF. Properdin: initiation of alternative complement pathway. Proc. Natl Acad. Sci. USA 72:3220–3224, 1975.PubMedGoogle Scholar
  25. 25.
    Biesecker G. Membrane attack complex of complement as a pathologic mediator. Lab. Invest. 49:237–249, 1983.PubMedGoogle Scholar
  26. 26.
    Kim S-H, Carney DF, Hammer CH, Shin ML. Nucleated cell kilhng by complement: effects of C5b-9 channel size and extracellular Ca2+ on the lytic process. J. Immunol 138: 1530–1536, 1987.PubMedGoogle Scholar
  27. 27.
    Lovett D, Hansch G, Resch K, Gemsa D. Activation of glomerular mesangial cells by terminal complement components. Stimulation of prostanoid and interleukin-1 like factor release. Immunology 168:34–35, 1984.Google Scholar
  28. 28.
    Policy MJ, Nachman RL, Weksler BB. Human complement in the arachidonic acid transformation pathway in platelets. J. Exp. Med. 153:257–268, 1981.Google Scholar
  29. 29.
    Hansch GM, Seitz M, Marinotti G, Betz M, Rauterberg EW, Gemsa D. Macrophages release arachidonic acid, prostaglandin E2, and thromboxane in response to late complement components. J. Immunol. 133:2145–2150, 1984.PubMedGoogle Scholar
  30. 30.
    Adler S, Baker PJ, Johnson RJ, Ochi RF, Pritzl P, Couser WG. Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells. J. Clin. Invest. 77:762–767, 1986.PubMedGoogle Scholar
  31. 31.
    Wedmore CV, Williams TJ. Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature 289:646–650, 1981.PubMedGoogle Scholar
  32. 32.
    Weiss SJ. Tissue destruction by neutrophils. N. Engl. J. Med. 320:365–376, 1989.PubMedGoogle Scholar
  33. 33.
    Del Balzo UH, Levi R, Policy MJ. Cardiac dysfunction caused by purified human C3a anaphylatoxin. Proc. Natl. Acad. Sci. USA 82:886–890, 1985.PubMedGoogle Scholar
  34. 34.
    Ito BR, Roth DM, Engler RL. Thromboxane A2 and peptidoleukotrienes contribute to the myocardial ischemia and contractile dysfunction in response to intracoronary infusion of complement C5a in pigs. Circ. Res. 66:596–607, 1990.PubMedGoogle Scholar
  35. 35.
    Piatt JL, Key NS, Dalmasso AP, Vercellotti GM, Lindman BJ, Bach FH. Complement mediated loss of endothelial cell proteoglycans. Kidney. Int. 37:599,1990 (Abstract).Google Scholar
  36. 36.
    Berden JH, Bogman MJ, Hageman FH, Tamboer WP, Koene RA. Complement-dependent and independent mechanisms in acute antibody-mediated rejection of skin xenografts in the mouse. Transplantation 32:265–270, 1981.PubMedGoogle Scholar
  37. 37.
    Berk BC, Alexander RW, Brock TA, Gimbrone Jr. MA, Webb RC. Vasoconstriction: a new activity for platelet-derived growth factor. Science 232:87–90, 1986.PubMedGoogle Scholar
  38. 38.
    Schwertschlag US, Dennis VW, Tucker JA, Camussi G. Non-immunological alterations of glomerular filtration by s-PAF in the rat kidney. Kidney Int. 34:779–785, 1988.PubMedGoogle Scholar
  39. 39.
    Armstead WM, Pourcyrous M, Mirro R, Leffler CW, Busija DW. Platelet activating factor: a potent constrictor of cerebral arterioles in newborn pigs. Circ. Res. 62: 1–7, 1988.PubMedGoogle Scholar
  40. 40.
    Camussi G, Tetta C, Coda R, Segohni GP, Vercellone A. Platelet-activating factor-induced loss of glomerular anionic charges. Kidney Int. 25:73–81, 1984.PubMedGoogle Scholar
  41. 41.
    Benveniste J, Boullet C, Brink C, Labat C. The actions of PAF-acether (platelet-activating factor) on guinea-pig isolated heart preparations. Br. J. Pharmacol. 80:81–83, 1983.PubMedGoogle Scholar
  42. 42.
    Ito S, Camussi G, Tetta C, Milgrom F, Andres G. Hyperacute renal allograft rejection in the rabbit: the role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets. Lab Invest. 51:148–161, 1984.PubMedGoogle Scholar
  43. 43.
    Whatley RE, Zimmerman GA, Mclntyre TM, Prescott M. Endothelium from diverse vascular sources synthesizes platelet-activating factor. Arteriosclerosis 8: 321–331, 1988.PubMedGoogle Scholar
  44. 44.
    Camussi G, Aglietta M, Malavasi F, Tetta C, Piacibello W, Sanavio F, Bussolino F. The release of platelet-activating factor from human endothelial cells in culture. J. Immunol. 131:2397–2403, 1983.PubMedGoogle Scholar
  45. 45.
    Bogman, MJ, Berden JH, Hagemann FH, Maass CN, Koene RA. Patterns of vascular damage in the antibody-mediated rejection of skin xenografts in the mouse. Am. J. Pathol. 100:727–738, 1980.PubMedGoogle Scholar
  46. 46.
    Bogman MJ, Berden JH, Cornelissen JM, Maass CN, Koene RA. The role of complement in the induction of acute antibody-mediated vasculitis of rat skin grafts in the mouse. Am. J. Pathol. 109:97–106, 1982.PubMedGoogle Scholar
  47. 47.
    Winn HJ, Baldamus CA, Jooste SV, Russell PS. Acute destruction by humoral antibody of rat skin grafted to mice. The role of complement and polymorphonuclear leukocytes. J. Exp. Med. 137:893–910, 1973.PubMedGoogle Scholar
  48. 48.
    Paul LC, Solez K. Chronic rejection of vascularized organ allografts. In: Organ Transplantation: Long Term Results. Paul LC, Solez K (eds.). Marcel Dekker Inc., New York (in press).Google Scholar
  49. 49.
    Reemtsma K, Pierson III RN, Marboe CC, Michler RE, Smith CR, Rose EA, Fenoglio JJ Jr. Will atherosclerosis limit chnical xenografting? Transplant Proc. 19 (suppl. 5): 108–118, 1987.PubMedGoogle Scholar
  50. 50.
    Ross R. The pathogenesis of atherosclerosis - an update. N. Engl. J. Med. 314:489–500, 1986.Google Scholar
  51. 51.
    Davies PF. Vascular cell interactions with special reference to the pathogenesis of atherosclerosis. Lab. Invest. 55:5–24, 1986.PubMedGoogle Scholar
  52. 52.
    Di Corleto PE, Bowen-Pope DF. Cultured endothelial cells produce a platelet-derived growth factor-like protein. Proc. Natl. Acad. Sci. USA 80:1919–1928, 1983.Google Scholar
  53. 53.
    Nilsson J, Sjolund M, Palmberg J, Thyberg J, Heldin C-H. Arterial smooth muscle cells in primary culture produce a platelet-derived growth factor-like protein. Proc. Natl. Acad. Sci. USA 82:4418–4422, 1985.PubMedGoogle Scholar
  54. 54.
    O’Connell TX, Mowbray JF. Arterial intimai thickening produced by alloantibody and xenoantibody. Transplantation 15:262–263, 1973.PubMedGoogle Scholar
  55. 55.
    Friedman RJ, Moore S, Singal DP. Repeated endothelial injury and induction of atherosclerosis in normolipemic rabbits by human serum. Lab. Invest. 30:404–415, 1975.Google Scholar
  56. 56.
    Leung DYM, Collins T, Lapierre LA, Geha RS, Pober JS. Immunoglobulin M antibodies present in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by gamma interferon. J. Clin. Invest. 11: 1428–1435, 1986.Google Scholar
  57. 57.
    Leung DYM, Geha RS, Newburger JW, Burns JC, Fiers W, Lapierre LA, Pober JS. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J. Exp. Med. 164:1958–1972, 1986.PubMedGoogle Scholar
  58. 58.
    Fedoroff S, Webb SJ. Natural cytotoxic antibodies in human blood sera which react with mammalian cells and bacteria. Nature 193:80–81, 1962.PubMedGoogle Scholar
  59. 59.
    Baumann A, Witebsky F. Un nouveau phenomene pour la demonstration de la toxicité du serum. Ann. Inst. Pasteur 53:282–289, 1934.Google Scholar
  60. 60.
    Perper RJ, Najarian JS. Experimental renal heterotransplantation. I. In widely divergent species. Transplantation 4: 377–388, 1966.PubMedGoogle Scholar
  61. 61.
    Rosenburg JC, Broersma RJ, Bullemer G, Mannen EF, Lenaghan R, Rosenberg BF. Relationship of platelets, blood coagulation and fibrinolysis to hyperacute rejection of renal xenografts. Transplantation 8:152–161, 1969.Google Scholar
  62. 62.
    Rosenberg JC, Hawkins E, Rector F. Mechanisms of immunological injury during antibody-mediated hyperacute rejection of renal heterografts. Transplantation 11: 151–157, 1971.PubMedGoogle Scholar
  63. 63.
    Gambiez L, Weil BJ, Chereau Ch, Calmus Y, Houssin D. The hyperacute rejection of guinea pig to rat heart xenografts is mediated by preformed IgM. Transplant. Proc. 22: 1058, 1990.Google Scholar
  64. 64.
    Moberg AW, Shons AR, Gewürz H, Mozes M, Najarian JS. Prolongation of renal xenografts by the simultaneous sequestration of preformed antibody, inhibition of complement, coagulation and antibody synthesis. Transplant. Proc. 3:538–541, 1971.PubMedGoogle Scholar
  65. 65.
    Rossman P, Matousovic K. The production of lesions in the rabbit kidney by xenoperfusion with fresh human blood. Virchows Arch. [A]. 382:95–111, 1979.Google Scholar
  66. 66.
    Lexer G, Cooper DKC, Wicomb WN, Rose AG, Rees J, Keraan M, Reichart B, Du Toit E. Cardiac transplantation using discordant xenografts in a nonhuman primate model. Transplant. Proc. 19:1153–1154, 1987.PubMedGoogle Scholar
  67. 67.
    Jamieson SW. Xenograft hyperacute rejection. A new model. Transplantation 17: 533–534, 1977.Google Scholar
  68. 68.
    Adachi H, Rosengard BR, Hutchins GM, Hall TS, Baumgartner WA, Borkon AM, Reitz B A. Effects of cyclosporine, aspirin, and cobra venom factor on discordant cardiac xenograft survival in rats. Transplant. Proc. 19:1145–1148, 1987.PubMedGoogle Scholar
  69. 69.
    Forbes RDC, Guttmann RD. Mechanisms of humoral-mediated cardiac allograft rejection in vivo: controlled, comparative morphological studies utilizing inbred rat models. Heart Transplantation 1:196–202, 1982.Google Scholar
  70. 70.
    Frangipane LG, Poole TW, Barker CF, Silvers WK. Vulnerabihty of allogeneic and xenogeneic pancreatic islets to alloantisera. Transplant. Proc. 9:371–373, 1977.PubMedGoogle Scholar
  71. 71.
    Perloff LJ, Naji A, Barker CF. Islet sensitivity to humoral antibody. Surg. Forum 32: 390–391, 1981.Google Scholar
  72. 72.
    Chabot J, Weber C, Hardy MA, Rivera S, Bailey-Braxton D, Strausberg L, Wood M, Chow J, Pi-Sunyer FX, Reemtsma K. Synergy of ALS and UV-B in prolongation of primate-to-mouse islet xenograft survival. Transplant. Proc. 19:1160–1165, 1987.PubMedGoogle Scholar
  73. 73.
    Baldamus CA, McKenzie IFC, Winn HJ, Russell PS. Acute destruction by humoral antibody of rat skin grafted to mice./. Immmunol. 110:1532–1541, 1973.Google Scholar
  74. 74.
    Valdivia LA, Monden M, Gotoh M, Hasuike Y, Kubota N, Endoh W, Okamura J, Mori T. Hepatic xenografts from hamster to rat. Transplant. Proc. 19:1158–1159, 1987.PubMedGoogle Scholar
  75. 75.
    Settaf A, Meriggi F, Van de Stadt J, Gane P, Crougneau S, Reynes M, Rouger P, Houssin D. Delayed rejection of liver xenografts compared to heart xenografts in the rat. Transplant. Proc. 19:1155–1157, 1987.PubMedGoogle Scholar
  76. 76.
    Iwatsuki S, Iwaki Y, Kano T, Klintmalm G, Koep LJ, Weil R, Starzl TE. Successful liver transplantation from crossmatch-positive donors. Transplant. Proc. 13: 286–290, 1981PubMedGoogle Scholar
  77. 77.
    Knechtle SJ, Kolbeck PC, Tsuchimoto S, Coundouriotis A, Sanfilippo F, Bollinger RR. Hepatic transplantation into sensitized recipients. Demonstration of hyperacute rejection. Transplantation 43:8–12, 1987.PubMedGoogle Scholar
  78. 78.
    Kano K, Milgrom F. Heterophile antigens and antibodies in medicine. Cur. Top. Microbiol. Immunol. 77:43–69, 1977.Google Scholar
  79. 79.
    Kashiwagi N, Brantigan CO, Brettschneider L, Groth CS, Starzl TE. Clinical reactions and serologic changes after the administration of heterologous antilymphocyte globulin to human recipients of renal homografts. Ann. Intern. Med. 68: 275–286, 1968.PubMedGoogle Scholar
  80. 80.
    McDonald JC. A heterophile system in human renal transplantation. II. Relationship to clinical renal transplantation and the HLA system. Transplantation 15: 123–126, 1973.PubMedGoogle Scholar
  81. 81.
    McDonald JC. A heterophile system in human renal transplantation. I. Distribution of antigens and reactivity of the antibodies. Transplantation 15:116–121, 1973.PubMedGoogle Scholar
  82. 82.
    Ehrlich P, Morgenroth J. Ehrlich Gesammelte Arbeiten. Vol. 2. Berlin-Heidelberg: Springer 1957.Google Scholar
  83. 83.
    Paul LC, Benediktsson H, Kingma I, Green BJ, Davidoff AW. Naturally-occurring and induced rat anti-guinea pig antibodies: tissue reactivity and specificity. Transplant. Proc. 22:1057.1990.Google Scholar
  84. 84.
    Nossal GJV. The induction of immunological tolerance in rats to foreign erythrocytes. Austral. J. Exp. Biol. 36:235–244, 1958.PubMedGoogle Scholar
  85. 85.
    Egdahl RH, Roller FR, Swanson DL, Varco RL. Acquired tolerance to homografts and heterografts in the rat. Ann. NY Acad. Sci. 73:842–847, 1958.PubMedGoogle Scholar
  86. 86.
    Michler RE, McManus RP, Smith CR, Sadeghi AN, Marboe CC, Reemtsma K, Rose EA. Prolongation of primate cardiac xenograft survival with cyclosporine. Transplantation 44:632–636, 1987.PubMedGoogle Scholar
  87. 87.
    Valdivia LA, Monden M. Gotoh M, Hasuike Y, Kubota N, Ichikawa T, Nakano Y, Okamura J, Mori T. An important role of the spleen in rejection of hamster-to-rat xenografts. Transplant. Proc. 20:329–331, 1988.Google Scholar
  88. 88.
    Linn BS, Jensen JA, Pardo V, Davies D, Franklin L. Relationship between structural and functional changes in rejecting renal xenograft. Transplant. Proc. 3:527–530, 1971.PubMedGoogle Scholar
  89. 89.
    Van de Stadt J, Vendeville B, Weill B, Crougneau S, Michel A, Filipponi F, Icard P, Renoux M, Lovel A, Houssin D. Discordant heart xenografts in the rat. Additional effect of plasma exchange and cyclosporine, cyclophosphamide, or splenectomy in delaying hyperacute rejection. Transplantation 45:514–518, 1988.PubMedGoogle Scholar
  90. 90.
    Valdivia LA, Monden M, Gotoh M, Hasuike Y, Kubota N, Ichikawa T, Okamura J, Mori T. Prolonged survival of hamster-to-rat liver xenografts using splenectomy and cyclosporine administration. Transplantation 44:759–763, 1987.PubMedGoogle Scholar
  91. 91.
    Pierson III RN, Winn HJ, Russell PS, Auchincloss Jr H. CD4+ lymphocytes play a dominant role in murine xenograft rejection. Transplant. Proc. 21:519, 1989.PubMedGoogle Scholar
  92. 92.
    Jugi T, Kano K, Milgrom F. Antibody induced lysis of nucleated cells in agar gel. Int. Arch. Allergy 41: 739–753, 1971.Google Scholar
  93. 93.
    Mori S, Kano K, Milgrom F. Heterophile antigen detectable by infectious mononucleosis sera on bone marrow cells. Int. Arch. Allergy 51:214–225, 1976.PubMedGoogle Scholar
  94. 94.
    Kasukawa R, Kano K, Bloom M, Milgrom F. Heterophile antibodies in pathologic human sera resembling antibodies stimulated by foreign species sera. Clin. Exp. Immunol. 25: 122–132:1916.Google Scholar
  95. 95.
    Siddiqui B, Hakomori S. A revised structure for the Forssman glycolipid hapten. J. Biol. Chem. 246:5766–5769, 1971.PubMedGoogle Scholar
  96. 96.
    Tanuka N, Leduc EH. A study of the cellular distribution of Forssman antigen in various species. J. Immunol. 11: 198–212, 1956.Google Scholar
  97. 97.
    Hawes MD, Coombs RRA. Cellular distribution of Forssman membrane antigen in the guinea pig determined by the mixed agglutination reaction. J. Immunol. 84: 586–589, 1960.PubMedGoogle Scholar
  98. 98.
    Leibowitz S, Morgan RS, Berkinshaw-Smith EMI, Payhng-Wright G. Cerebral vascular damage in guinea pigs induced by various heterophile antisera injected by the Forssman intracarotid technique. Brit. J. Exp. Path. 42:455–463, 1961.PubMedGoogle Scholar
  99. 99.
    Metzgar RS, Zmijewski CM. Species distribution of human tissue isoantigens. I. Detection of human tissue isoantigens in chimpanzees. Transplantation 4:84–93, 1966.Google Scholar
  100. 100.
    Balner H, Van Leeuwen A, Dersjant H, Van Rood JJ. Defined leukocyte antigens of chimpanzees: use of chimpanzee isoantisera for leukocyte typing in man. Transplantation 5:624–642, 1967.PubMedGoogle Scholar
  101. 101.
    Balner H, Van Leeuwen A, Van Vreeswijk W, Dersjant H, Van Rood J J. Leukocyte antigens of chimpanzees and their relation to human HL-A antigens. Transplant. Proc. 2:454–462, 1970.PubMedGoogle Scholar
  102. 102.
    Dorf ME, Eguro SY, Amos DB. Cross-reactions of HL-A antibodies. IV. Absorptions and elutions with primate platelets. Transplant. Proc. 4:71–75, 1972.PubMedGoogle Scholar
  103. 103.
    Gotze D (ed). The Major Histocompatibility System in Man and Animals. Springer-Verlag, Berlin, Heidelberg, New York, 1977.Google Scholar
  104. 104.
    Staines NA. Relative immunogenicity of H-2 and other membrane components in xenoimmunization. Transplantation 17:470–476, 1974.PubMedGoogle Scholar
  105. 105.
    Sachs DH, Cone JL. A mouse B-cell alloantigen determined by gene(s) linked to the major histocompatibihty complex. J. Exp. Med. 138:1289–1304, 1977.Google Scholar
  106. 106.
    Turman MA, Casali P, Notkins AL, Fischel RJ, Lindman BJ, Vercellotti GM, Bach FH, Platt JL. Human monoclonal and polyclonal xenoreactive natural antibodies (XNA). Kidney Int. 37:601,1990 (Abstract).Google Scholar
  107. 107.
    Miyagawa S, Hirose H, Shirakura R, Naka Y, Nakata S, Kawashima Y. Seya T, Matsumoto M. Uenaka A, Kitamura H. The mechanism of discordant xenograft rejection. Transplantation 46:825–830, 1988.PubMedGoogle Scholar
  108. 108.
    Larsen S, Starklint H, Dieperink H, Kemp E. Immunofluorescence microscopy in experimental renal alio- and xenografts. Transplant. Proc. 22: 1061–1062, 1990.PubMedGoogle Scholar
  109. 109.
    Cochrane CG, Muller-Eberhard HJ, Aikin BS. Depletion of plasma complement in vivo by a protein of cobra-venom: its effect on various immunologic reactions. J. Immunol. 105:55–69, 1970.PubMedGoogle Scholar
  110. 110.
    Vogel CW, Smith CA, Muller-Eberhard HJ. Cobra venom factor: structural homology with the third component of human complement. J. Immunol. 133:3235–3241, 1984.PubMedGoogle Scholar
  111. 111.
    Rosengard BR, Hall TS, Imagawa DK, Ueda K, Baumgartner WA, Borkon M, Smith RRL, Hutchins GM, Reitz BA. Hyperacute rejection of cardiac xenograts: two new models showing differences in pathogenesis. Surg. Forum 36:361–365, 1985.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • L. C. Paul

There are no affiliations available

Personalised recommendations